ENVERIC BIOSCIENCES INC
ENVBNASDAQTrading Snapshot
- Day Range
- $1.45 – $1.49
- 52-Week Range
- $1.17 – $13.25
- Volume
- $1.92B
- Avg Volume
- $1.98B
- Shares Outstanding
- 597,012
- Next Earnings
- Oct 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $56,794
- Last Q Revenue
- $13,129
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.19
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1845.0%
Why Investors Own ENVB
- ✓High-growth profile — revenue up +35.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ENVERIC BIOSCIENCES INC
ENVB
StockOtter · stockotter.spaceAbout ENVERIC BIOSCIENCES INC
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurolog
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurolog
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurologic
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003.
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurolog
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurolog